Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

“…14,16,17 However, some others studies agree with ours in regard to the lack of clinical significance of the immunophenotypic profiles in patients treated with immunochemotherapy. 18 Several factors may account for these discrepancies, including the population studied and the methodology used. First, retrospective analysis of a heterogeneous series with different therapies may have confounded the results.…”

“…In addition, the categorization of DLBCL into a GCB or non-GCB subgroup was shown to be associated with clinicopathologic features of tumors and predicted patient outcome in some studies but not in others. [13][14][15][16][17][18][19][20][21][22][23] The reasons for these contradictory results may be complex, and include difficulties in the standardization of both the staining methodologies and evaluation of the results 24 and heterogeneity in the characteristics of the patients in the different studies. [13][14][15][16][17][18] However, it is not clear whether any of the algorithms is superior to the others in obtaining GEP molecular information, because a comparative study using all of them has not been performed and only 3 studies have associated the immunophenotypic algorithm with the GEP molecular classification.…”

CD4+ Tumor infiltrating lymphocytes are prognostic and independent of R‐IPI in patients with DLBCL receiving R‐CHOP chemo‐immunotherapy

“…T H 1 cells in particular stimulate and upregulate antigen presentation and tumor clearance [21]. Improved antigen presentation has been shown to be a key survival determinant in patients with DLBCL [22][23][24]. These animal models have shown that cytokines derived from T H 1 cells such as interferon-gamma, interleukin-1, and TNF-alpha are important in stimulating tumor-associated macrophages.…”

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

“…This is reminiscent of the inferior outcome of immunoblastic lymphomas with changes in chromosome 8q as shown by cytogenetics and the high percentage of MYC breaks and the predominance of IG-MYC translocations in plasmablastic lymphomas and could contribute to the inferior outcome of immunoblastic lymphomas. [51][52][53] Although the present study has the limitation of being retrospective and only a minority of the patients received immuno-chemotherapy, we would nevertheless recommend screening all patients with DLBCL and DLBCL/BL intermediate, irrespectively of immunophenotypic features including Ki67 5,12,15 and MYC expression, for MYC rearrangements in the diagnostic work up. Since an accompanying BCL2 and/or BCL6 breakpoint exists in 20-80% (in our study 60%) of MYC + lymphomas other than BL, 12-16 FISH for these genes could still be used to identify the majority of MYC + lymphomas other than mBL.…”